Share on StockTwits

Opko Health (NYSE:OPK) CEO Phillip Md Et Al Frost bought 36,200 shares of the company’s stock on the open market in a transaction that occurred on Friday, April 25th. The stock was purchased at an average price of $8.04 per share, with a total value of $291,048.00. Following the completion of the transaction, the chief executive officer now directly owns 1,987,500 shares of the company’s stock, valued at approximately $15,979,500. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Separately, analysts at Oppenheimer initiated coverage on shares of Opko Health in a research note on Thursday, March 13th. They set an “outperform” rating and a $13.00 price target on the stock. One investment analyst has rated the stock with a hold rating and three have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $12.83.

Shares of Opko Health (NYSE:OPK) traded up 1.24% on Monday, hitting $8.15. The stock had a trading volume of 328,240 shares. Opko Health has a 52 week low of $6.14 and a 52 week high of $12.95. The stock has a 50-day moving average of $9.08 and a 200-day moving average of $9.36. The company’s market cap is $3.365 billion.

Opko Health (NYSE:OPK) last issued its quarterly earnings data on Monday, March 3rd. The company reported ($0.04) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.05) by $0.01. The company had revenue of $20.70 million for the quarter, compared to the consensus estimate of $23.64 million. Opko Health’s revenue was up 27.8% compared to the same quarter last year. Analysts expect that Opko Health will post $-0.38 EPS for the current fiscal year.

OPKO Health, Inc (NYSE:OPK), incorporated in October 1991, is a multi-national pharmaceutical and diagnostics company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.